Hangzhou DAC Biotech

What Hangzhou DAC Biotech does

Hangzhou DAC Biotech (杭州多禧生物科技有限公司) is a clinical-stage Chinese biopharmaceutical company founded in December 2012 in Hangzhou, specializing in the discovery, development, and manufacturing of Antibody-Drug Conjugate (ADC) therapeutics for cancer. The company operates one of China's most extensive ADC technology platforms, built on two proprietary pillars: the CrossConju™ site-specific conjugation chemistry, which enables precise attachment of cytotoxic payloads at defined positions on antibodies, and the CPT113 Topo1 inhibitor payload-linker system, which delivers camptothecin-based warheads via a stable linker. Its platform covers five categories of small-molecule cytotoxic payloads (Tubulysin, Amanitin, PBD, Camptothecin/Topo1, Duocarmycin) with over 100 compounds developed internally, plus antibody generation, ADC characterization via LC-MS, and full-scale GMP manufacturing capacity for both antibodies and ADC drug product.

The company monetizes exclusively through B2B licensing and co-development agreements with global pharmaceutical partners, generating upfront payments, development and regulatory milestones, commercial milestones, and royalties — with no approved products and no direct commercial sales. Its clinical pipeline comprises eight ADC candidates including DX126-262 (HER2, Phase II, US multi-center), DAC-002/JS108 (Trop2, partnered with Junshi Biosciences), DXC005 (MUC1), DXC006 (CD56, first-in-class with 75.0% ORR in second-line small-cell lung cancer reported at ASCO 2026), DXC007 (CD33/AML), DXC009 (BCMA/multiple myeloma), DXC004A, and DXC1002. Strategic partners include Johnson & Johnson (Janssen) for up to five ADC programs, Aadi Bioscience for three preclinical candidates ($44M upfront plus up to $805M in milestones), Junshi Biosciences (DAC-002 Trop-2 license), WuXi Biologics (manufacturing collaboration), and Whitehawk Therapeutics (CPT113 option for five programs). The company is backed by GL Ventures, CDB Capital, CPE, and other Chinese healthcare investors after a 1 billion RMB Series C in May 2021, holds 700+ patent applications across 30+ countries including 35 granted US patents, and has been repeatedly recognized on Chinese pharmaceutical innovation rankings from 2020 through 2025.

Name

Hangzhou DAC Biotech

Legal name

杭州多禧生物科技有限公司

Website

https://dacbiotech.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Hangzhou DAC Biotech is a clinical-stage Chinese biopharmaceutical company developing proprietary Antibody-Drug Conjugate (ADC) cancer therapies, monetizing through B2B licensing and co-development partnerships with global pharmaceutical companies including Johnson & Johnson, Aadi Bioscience, and Junshi Biosciences.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Bispecific & Multispecific Antibodies (HLAAAAAF)

Keywords

• Antibody-drug conjugates
• ADC drug development
• Oncology therapeutics
• Biopharmaceutical licensing
• Site-specific conjugation

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Licensing and Milestone Payments: The company generates revenue through licensing deals with pharmaceutical companies, receiving upfront payments, development and regulatory milestones, and commercial milestones for ADC products developed using its proprietary technology platforms

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Hangzhou DAC Biotech discovers, develops, and manufactures Antibody-Drug Conjugate (ADC) therapeutics for cancer using proprietary platforms including the CrossConju™ site-specific conjugation technology and CPT113 Topoisomerase I inhibitor payload-linker system. The company licenses its ADC technology platforms and pipeline candidates to global pharmaceutical partners for co-development and commercialization, and operates GMP-compliant antibody and ADC drug manufacturing.

Product overview

Hangzhou DAC Biotech is a clinical-stage biopharmaceutical company specializing in Antibody-Drug Conjugate (ADC) drug discovery, development, and manufacturing. The company has established a comprehensive ADC technology platform with proprietary technologies including the CPT113 Topo1 inhibitor payload-linker system, CrossConju™ site-specific conjugation technology, over 100 small molecule cytotoxic compounds across 5 categories, and advanced antibody engineering capabilities. The product portfolio includes multiple ADC drug candidates at various clinical stages: DX126-262 (HER2), DAC-002/Trop2, DXC005 (MUC1), DXC006 (CD56, first-in-class), DXC007 (CD33), DXC009 (BCMA), DXC004A, and DXC1002. The company operates GMP-compliant manufacturing facilities for both antibody and ADC drug production with annual capacity of tens of thousands of vials. The company collaborates with global pharmaceutical partners including Johnson & Johnson, WuXi Biologics, Junshi Biosciences, and Aadi Bioscience.

Differentiator

Problem solved

Functional benefit

Named customers5 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• Whitehawk TherapeuticscoreStrategic or Co-development Partner · 1 January 2026Option agreement for CPT113 linker-payload technology, giving Whitehawk Therapeutics the option to license DAC Biotech's proprietary CPT113 Topo1 inhibitor payload-linker technology.
• Aadi BiosciencecoreStrategic or Co-development Partner · 1 January 2024Collaboration agreement for the development of 3 ADC candidates using DAC Biotech's proprietary platforms. Aadi Bioscience gains access to DAC's ADC technology for advancing its oncology pipeline.
• Johnson & Johnson (Janssen)flagshipStrategic or Co-development Partner · 1 January 2022Collaboration and license agreement for the development of ADC drugs using DAC Biotech's proprietary technology platforms. This represents one of the company's most significant global partnerships, validating the quality of its ADC technology internationally.
• WuXi Biologics (药明生物)coreTechnology or IntegrationStrategic partnership for ADC development combining WuXi Biologics' biologics development and manufacturing capabilities with DAC Biotech's ADC platform technologies.
• Junshi Biosciences (君实生物)coreStrategic or Co-development PartnerLicense agreement for Trop-2 ADC (DAC-002/JS108), granting Junshi Biosciences rights to develop and commercialize the ADC candidate for cancer treatment.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• ProfoundBio: ProfoundBio is a US/China clinical-stage ADC company with proprietary payloads (including Topo1-based exatecans) and conjugation technology. It is a direct peer in the global ADC platform out-licensing space, with overlapping targets and partner-type deals.
• Mersana Therapeutics: Mersana is a US clinical-stage ADC platform company with proprietary conjugation technologies (Dolasynthen, DAF) and ImmunoLyn payload platforms. It is a direct peer in the technology-platform-licensing ADC model that DAC Biotech operates.
• RemeGen Co., Ltd. RemeGen is a Chinese clinical-stage biotech with a deep ADC pipeline (e.g., disitamab vedotin, multiple ADCs in oncology). Like DAC Biotech, it develops and out-licenses ADC products and competes head-to-head in China's ADC innovation rankings and global out-licensing markets.
• Pyxis Oncology: Pyxis Oncology is a US clinical-stage oncology company developing ADCs and immunotherapies using proprietary linker-payload and antibody technology. It is a direct peer in the differentiated ADC platform space with similar partnership-driven economics.
• Tubulis GmbH: Tubulis is a German biotech developing next-generation ADCs with proprietary P5 conjugation chemistry and tumor-selective payload-linker platforms. It is a direct platform peer focused on differentiated conjugation and linker technologies for ADC out-licensing.

Broad incumbents

• AstraZeneca: AstraZeneca is a global ADC leader through its Enhertu collaboration with Daiichi Sankyo and expanding internal ADC programs. As a broad incumbent, it both competes for ADC market share and serves as a potential acquirer/licensor of platform technologies like DAC Biotech's.
• Daiichi Sankyo: Daiichi Sankyo pioneered the DXd ADC technology platform (Enhertu, Datroway) and is the dominant commercial ADC incumbent. It is a broad incumbent whose validated Topo1 payload approach directly competes with DAC Biotech's CPT113 platform strategy.

Regional players

• Innovent Biologics: Innovent is a leading Chinese biotech with multiple oncology ADCs in development (including partnerships with Eli Lilly) and a large commercial biologics franchise. It is a regional peer competing in Chinese ADC innovation rankings and out-licensing to global pharma.
• Hansoh Pharmaceutical Group: Hansoh is one of China's largest innovative pharma companies with a growing ADC pipeline and platform investments. It is a regional peer competing for the same Chinese out-licensing deals, oncology talent, and global partnership opportunities as DAC Biotech.

Others

• WuXi XDC (WuXi AppTec ADC business): WuXi XDC is a global CRDMO dedicated to ADCs, providing discovery, development, and manufacturing services. It is an ecosystem enabler and existing strategic partner of DAC Biotech rather than a direct competitor, but it shapes the competitive supply landscape for Chinese ADC biotechs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hangzhou-dac-biotech-co.-ltd.

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hangzhou DAC Biotech